Abstract
The transdermal administration of nicotine by means of a transdermal nicotine system (TNS) affords a novel way of nicotine replacement to alleviate smoking cessation. The plasma levels of nicotine maintained with the TNS are in the range of the footpoint concentrations observed in smokers. The efficacy of the TNS was investigated in two placebo-controlled double-blind smoking cessation programs with minimal contact and minimal psychological support. A total of 311 smokers were treated for 3 months or 9 weeks. The abstinence rates at the end of the treatment and weaning periods were almost doubled in the TNS groups (36% and 39%) as compared to the placebo groups (23% and 20%) with a significant difference for both studies (p<0.05). These data suggest that the TNS can also improve the smoking cessation rates under the conditions of general medical advice, making it suitable for use outside of specialized smoking cessation centers.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
U.S. Department of Health Office on Smoking (1988) The Health Consequences of Smoking: Nicotine Addiction. A report of the Surgeon General, 1988. U.S. Government Printing Office, Washington, DC, p 2040
Russell, MAH, Jarvis MJ (1985) Theoretical background and clinical use of nicotine chewing gum. National Institute on Drug Abuse. Res Monogr 53:110–130
Dubois JP, Sioufi A, Müller Ph, Mauli D, Imhof PR (1989) Pharmacokinetics and bioavailability of nicotine in healthy volunteers following single and repeated administration of different doses of transdermal nicotine systems. Methods Findings Exp Clin Pharmacol 11:187–195
Müller Ph, Imhof PR, Mauli D, Milovanovic D (1989) Human pharmacological investigations of a transdermal nicotine system. Methods Findings Exp Clin Pharmacol 11:197–204
Müller Ph, Schlösser R, Imhof P, Dubach UC, Sioufi A (1988) Haemodynamic and humoral effects of cigarette smoking. In: Aoki M, Hisamichi S, Tominaga S (eds) Smoking and health 1987. Excerpta Medica, Elsevier Science Publishers, Amsterdam—New York—Oxford, 739–741
Sioufi A, Parisot C, Sandrenan N, Dubois JP (1989) High performance liquid chromatographic determination of nicotine and cotinine in plasma and nicotine and cotinine, simultaneously, in urine. Methods Findings Exp Clin Pharmacol 11:179–185
Abelin T, Bühler A, Müller P, Vesanen K, Imhof PR (1989) Controlled trial of transdermal nicotine patch in tobacco withdrawal. Lancet I:7–10
Abelin TH, Ehrsam R, Bühler-Reichert A, Imhof PR, Müller Ph, Thommen A, Vesanen K (1989) Effectiveness of a transdermal nicotine system in smoking cessation studies. Methods Findings Exp Clin Pharmacol 11:205–214
Fagerström K-O (1978) Measuring degree of physical dependence to tobacco smoking with reference to individualization of treatment. Addict Behav 3:235–241
West R, Schneider N (1987) Craving for cigarettes. Br J Addict 82:407–415
Research Committee of the British Thoracic Society (1983) Comparison of four methods of smoking withdrawal in patients with smoking-related diseases. Br Med J 286:595–597
Lam W, Sze PC, Sacks HS, Chalmers TC (1987) Meta-analysis of randomised controlled trials of nicotine chewing-gum. Lancet II:27–30
Russell MAH, Merriman R, Stapleton J, Taylor W (1983) Effect of nicotine chewing gum as an adjunct to general practitioners’ advice against smoking. Br Med J 287:1782–1785
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Müller, P., Abelin, T., Ehrsam, R. et al. The use of transdermal nicotine in smoking cessation. Lung 168 (Suppl 1), 445–453 (1990). https://doi.org/10.1007/BF02718163
Issue Date:
DOI: https://doi.org/10.1007/BF02718163